15.23
0.85%
-0.13
After Hours:
15.23
Celcuity Inc stock is traded at $15.23, with a volume of 107.98K.
It is down -0.85% in the last 24 hours and up +1.26% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$15.36
Open:
$15.33
24h Volume:
107.98K
Relative Volume:
0.45
Market Cap:
$550.64M
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-5.7472
EPS:
-2.65
Net Cash Flow:
$-53.91M
1W Performance:
-4.27%
1M Performance:
+1.26%
6M Performance:
-13.81%
1Y Performance:
+42.60%
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Celcuity Inc Stock (CELC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-22-24 | Initiated | Leerink Partners | Outperform |
Feb-22-24 | Initiated | Stifel | Buy |
Dec-08-23 | Initiated | H.C. Wainwright | Buy |
Oct-08-21 | Initiated | Canaccord Genuity | Buy |
Sep-07-21 | Initiated | Jefferies | Buy |
Jul-29-21 | Initiated | Cowen | Outperform |
Jul-27-21 | Initiated | Needham | Buy |
Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
May-11-20 | Resumed | Craig Hallum | Buy |
Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Analysts Set Celcuity Inc. (NASDAQ:CELC) PT at $29.17 - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Short Interest Up 9.3% in October - MarketBeat
Celcuity director Buller sells $5,687 in stock - Investing.com India
Celcuity director Buller sells $5,687 in stock By Investing.com - Investing.com Australia
Objective long/short (CELC) Report - Stock Traders Daily
Short Interest in Celcuity Inc. (NASDAQ:CELC) Rises By 26.7% - MarketBeat
Celcuity Inc. expands share authorization to 95 million By Investing.com - Investing.com Australia
Celcuity Inc. expands share authorization to 95 million - Investing.com India
Celcuity (NASDAQ:CELC) Files 8-K Disclosing Change in Directors or Principal Officers - MarketBeat
Celcuity (NASDAQ:CELC) Stock Price Down 4.5%Here's What Happened - MarketBeat
Morgan Stanley's Strategic Reduction in Celcuity Inc Holdings - GuruFocus.com
Stifel raises Celcuity stock price target, maintains buy on sales potential - Investing.com
Celcuity (NASDAQ:CELC) PT Raised to $42.00 at Stifel Nicolaus - MarketBeat
Brokerages Set Celcuity Inc. (NASDAQ:CELC) PT at $28.67 - MarketBeat
Point72 Asset Management L.P. Buys New Position in Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Driehaus Capital Management LLC Purchases 78,525 Shares of Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Short Interest Up 11.4% in September - MarketBeat
(CELC) Investment Report - Stock Traders Daily
Blue Owl Capital Holdings LP Takes $1.07 Million Position in Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Samlyn Capital LLC Purchases 637,190 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity Inc. (NASDAQ:CELC) Shares Acquired by Samlyn Capital LLC - MarketBeat
It is Poised to be a Bull Market for Celcuity Inc (CELC) - SETE News
(CELC) Technical Pivots with Risk Controls - Stock Traders Daily
Celcuity Inc. (NASDAQ:CELC) Short Interest Update - MarketBeat
Ratios Revealed: Decoding Celcuity Inc (CELC)’s Financial Health - The Dwinnex
Celcuity (NASDAQ:CELC) Sees Large Volume Increase - MarketBeat
Celcuity (NASDAQ:CELC) Shares Down 3.5% - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Celcuity (CELC) Holds a Potential Game-changer in Cancer Treatment - Nasdaq
Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
How To Trade (CELC) - Stock Traders Daily
Ready to Jump After Recent Trade: Celcuity Inc (CELC) - SETE News
Is Celcuity (NASDAQ:CELC) Using Too Much Debt? - Simply Wall St
Celcuity director sells shares worth $5,932 By Investing.com - Investing.com Australia
Celcuity director sells shares worth $5,932 - Investing.com India
Celcuity (NASDAQ:CELC) Coverage Initiated by Analysts at Lifesci Capital - MarketBeat
Celcuity (NASDAQ:CELC) Now Covered by Lifesci Capital - Defense World
Wall Street analysts’ outlook for Celcuity Inc (CELC) - SETE News
LifeSci Capital Initiates Coverage of Celcuity (CELC) with Outperform Recommendation - MSN
Celcuity Inc (CELC) presents a great opportunity, but the stock is slightly undervalued - US Post News
Hennion & Walsh Asset Management Inc. Invests $888,000 in Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Celcuity (CELC) Upgraded to Buy: Here's Why - Yahoo Finance
Earnings call: Celcuity reports Q2 loss, progresses on gedatolisib trials - Investing.com
Celcuity Inc. (NASDAQ:CELC) Q2 2024 Earnings Call Transcript - Insider Monkey
Celcuity Inc. (NASDAQ:CELC) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Celcuity (NASDAQ:CELC) Shares Gap Up to $16.33 - Defense World
Celcuity (NASDAQ:CELC) Stock Rating Reaffirmed by HC Wainwright - Defense World
Celcuity Inc. (NASDAQ:CELC) Receives Consensus Rating of “Buy” from Analysts - Defense World
Celcuity (NASDAQ:CELC) Rating Reiterated by Needham & Company LLC - Defense World
Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):